Michael R. Hayden - 07 Dec 2021 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role: Director
Signature: /s/ Tryn Stimart, attorney in fact
Issuer symbol: ABCL
Transactions as of: 07 Dec 2021
Net transactions value: $0
Form type: 4
Filing time: 10 Dec 2021, 12:13:46 UTC
Previous filing: 19 Oct 2021
Next filing: 30 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ABCL	Common Shares						1,273,397	07 Dec 2021	See footnote	F1
holding	ABCL	Common Shares						118,245	07 Dec 2021	By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABCL	Share option (right to buy)	Award	$0	+34,282	+5.4%	$0.000000	674,282	27 Aug 2021	Common Shares	34,282	$17.58	Direct
transaction	ABCL	Share option (right to buy)	Award	$0	+45,532	+11%	$0.000000	449,814	07 Dec 2021	Common Shares	45,532	$14.55	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.